News

C4X Discovery (C4XD) has launched PatientSeek, a precision medicine platform that can help identify which people, including those with Parkinson’s disease, will likely benefit most from new therapies, based on their genetics. The launch follows a research collaboration with the Garvan Institute of Medical Research, Australia, which validated…

Women using a specific type of blood cholesterol-lowering medication, called lipophilic statins, for at least five years may have a lower risk of developing Parkinson’s disease, according to data from more than 70,000 women followed for 15 years in France. The results showed a dose-dependent effect, with lower Parkinson’s…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second $500,000 grant to NRG Therapeutics supporting more research into its potential disease-modifying therapy for Parkinson’s disease. The new funding comes after the successful completion of a previous MJFF-funded project that set out to investigate how NRG’s small…

Among several atypical antipsychotics, Nuplazid (pimavanserin) seems to be the most effective at easing Parkinson’s disease psychosis (PDP) while sparing motor function, according to a review study. Clozapine, used off-label in people with Parkinson’s, also helped, but its effect was not as large and patients were more…

Deep brain stimulation (DBS) is more effective at easing nonmotor symptoms and improving life quality for people with the postural instability and gait disturbance (PIGD) subtype of Parkinson’s disease than for those with the tremor-dominant (TD) subtype, a study showed. While previous studies have suggested different effects of…

LisCure Biosciences is teaming up with Celltrion to identify and develop oral therapies targeting the gut microbiome — the population of microorganisms living in the gastrointestinal tract —for people with Parkinson’s disease, the company announced. Under the collaboration, the South Korean companies aim to develop orally available live biotherapeutic…

Certain regulators of protein balance are suppressed in people with sporadic Parkinson’s disease and in those with familial disease linked to G2019S, the most common disease-causing LRRK2 gene variant, according to a study of patient-derived skin cells. These findings suggest shared underlying mechanisms between both types of Parkinson’s,…

People with Parkinson’s disease are at a higher risk of simultaneous autoimmune diseases where the immune system erroneously attacks the body, according to a review study. Pooled data from multiple studies showed a significantly increased risk of Parkinson’s combined with either bullous pemphigoid, a rare skin condition, inflammatory bowel…

Older Parkinson’s patients undergoing deep brain stimulation (DBS), those in their 60s and 70s at the time of the surgical procedure, as well as those diagnosed at older ages are at a higher risk of death over the following years, according to a nationwide study in South Korea.

Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild cognitive impairment (MCI) due to Parkinson’s disease. The trial is recruiting Parkinson’s patients at 16 sites across the U.S. Dubbed PRECEDENT (NCT05318937), it’s designed to investigate SAGE-718’s…